Object. Focal tumors, a distinct subgroup of which is composed of brainstem gliomas, may have an indolent clinical course. In the past, their management involved monitoring of open-ended imaging studies and shunt placement if cerebrospinal fluid diversion was required. Nonetheless, their treatment remains a significant challenge for neurosurgeons. Gamma Knife surgery (GKS) has recently been tried as an alternative to surgical extirpation. In the present study the authors assess clinical and imaging results in 20 patients who harbored focal brainstem gliomas treated with GKS between 1990 and 2001.
FTER extensive use in the neurosurgical management of intracranial neoplasms, GKS has also been used for treating glial tumors. 16, 25 Its use for high-grade astrocytomas remains controversial, despite several reports of successful control of infiltrating tumors. 12, 25, 30, 33, 49 However, GKS, which was originally devised for well-defined and deep-seated lesions, has emerged as an alternative tool for treating focal brainstem gliomas. 3, 16, 18, 19, 23 Although the radiobiological effects of the narrow beams in GKS remain to be clarified, evidence is accumulating that cytotoxic effects, obliteration of nutritive vessels, and apoptotic cell death contribute to the efficacy of the treatment. 26, 45 We report a consecutive series of 20 patients with focal gliomas in the brainstem treated with GKS.
Clinical Material and Methods

Patient and Tumor Characteristics
Between February 1990 and October 2001, 20 patients with focal brainstem gliomas were treated with GKS at the University of Virginia Health System's Lars Leksell Center for Gamma Surgery ( Table 1) . The study population consisted of 10 male and 10 female patients, with a mean age of 19.1 years (median 13 years, range 4-64 years). All patients presented with progressive tumor growth and/or neurological deficits. The focal tumors were located in the midbrain in 16 patients, the pons in three, and the medulla oblongata in one. Of 16 midbrain tumors, 13 were located in the tectum, two in the tegmentum, and one in the cerebral peduncle. Three midbrain tumors also involved the rostral pons, and one invaded the basal thalamus. All gliomas were intrinsic tumors with the exception of two that were postoperative residuals of dorsal exophytic tumors.
Symptoms of increased intracranial pressure caused by obstructive hydrocephalus were the most common clinical manifestations of the focal tumors; these symptoms were present in 14 patients (12 with tectal tumors, one with a tegmentum tumor, and one with a medulla oblongata tumor). Tumors in 13 patients had been managed with a VP shunt before GKS. The neurological deficits of the study population varied depending on the size and location of tumors, including long tract signs in four patients, cranial nerve palsies in eight, cerebellar signs in four, and seizure in one. One patient with a tectal tumor but no neurological deficit complained of nonspecific mild headache and fatigue. Another patient with an exophytic pontine tumor was found to have neurofibromatosis. Histopathological diagnoses included five pilocytic astrocytomas and five nonpilocytic, low-grade gliomas, obtained by stereotactic biopsy procedures in five patients and open microsurgery in five. The diagnoses of the tumors in the remaining 10 patients were based on clinical and imaging findings. The mean latency from the onset of clinical symptoms to the diagnosis of the tumor was 31.9 months (range 0.5-132 months). The KPS scores at the time of GKS were 90 in 16 patients and 80 in four. One patient received conventional radiotherapy before GKS, and one underwent radiotherapy after GKS. No patients received chemotherapy.
All tumors showed a relatively well-defined margin with abnormal signals, which were typically hypointense or isointense on T 1 -weighted and hyperintense on T 2 -weighted MR images. Four tumors were homogeneously enhanced, and three had a partially enhancing nodule at the periphery. There was no enhancement at all in the other 13 tumors. The mean tumor volume at the time of GKS was 2.5 cm 
Gamma Knife Surgery Technique
The GKS procedure has been detailed elsewhere. 47 In pediatric patients, the placement of the stereotactic frame and the entire treatment procedure were performed after induction of general anesthesia. In adult patients, a local anesthetic supplemented with intravenous sedation was used only during the placement of the frame. Before 1990, CT scanning was the only imaging modality available for treatment planning; after 1990, MR imaging was used. Until July 2001, GKS was performed using the Leksell Gamma Unit, model U, and thereafter the C model was used (Elekta Instruments, Inc.). The dose rate varied, ranging from 3.66 Gy/minute in March 1989 to 1.59 Gy/minute in October 1995, when the cobalt source was reloaded, and from 3.56 Gy/minute in November 1995 to 2.31 Gy/minute in July 2001, when the model C was installed. The dose rate of the model C unit ranged from 3.67 Gy/minute in July 2001 to 3.55 Gy/minute in October 2001. The KULA software was used for dose planning from 1989 to June 1994, and was then replaced with GammaPlan software (Elekta Instruments, Inc.).
A mean dose of 12.8 Gy (median 13.5 Gy; range 4-18 Gy) was given to the tumor margin prescribed to an isodose configuration ranging from 30 to 70% (median 45%). The mean maximum dose was 29.8 Gy (median 30 Gy, range 10-43.3 Gy). The average number of isocenters used per patient was four (range 1-9 isocenters). The peripheral doses varied between 10 and 18 Gy, except in two adult patients with additional fractionated radiotherapy (one given 64.5
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Gamma Knife surgery for brainstem gliomas 9 Gy and the other given 40 Gy) and one patient with planned but unfulfilled radiotherapy (due to patient's refusal); these three patients received only boost doses of 4, 7, and 5 Gy, respectively.
Follow-Up Evaluation
Clinical follow-up data were obtained by examining the patients, communicating verbally, or in writing with the patients and the referring physicians. Follow-up MR imaging was repeated every 3 months for the first year and thereafter at 6-month intervals. Additional imaging studies were performed in the interim if the patients developed new or worsening clinical symptoms. Special software that was developed at our center was used to calculate tumor volumes seen on all films, and these calculations were reviewed by neurosurgeons and neuroradiologists. The reliability of the calculation method depends on the numbers of slices that show the tumors. 46 Other changes noted during imaging studies were also detailed and recorded.
Statistical Analysis
Imaging outcome was analyzed using the nonparametric independent t-test for univariate analysis of continuous variables (age, KPS score, peripheral dose, maximum dose, isodose configuration, number of isocenters, tumor volume, interval duration between the diagnosis of brainstem tumor and GKS, and duration of imaging follow up) and the chisquare test for dichotomous variables (sex, pilocytic or nonpilocytic tumor [pathology], tectal or nontectal location, enhancing or nonenhancing tumor, and degree of increased enhancement in the tumor following GKS). Logistic regression was used for multivariate analysis. The tumor control rate was analyzed using the Kaplan-Meier method. All statistical analyses in the study were performed using a commercially available software package (SPSS version 10.1; SPSS, Inc.). Statistical significance was set at a probability level of less than 0.05.
Results
Illustrative Cases
Case 1. This 56-year-old woman had a tectal tumor with obstructive hydrocephalus. She had been asymptomatic following insertion of a shunt. Fractionated radiation was performed with a total dose of 64.8 Gy, but tumor progression prompted GKS in 1993 with 4 Gy to the tumor margin. The tumor started to shrink 9 months after GKS and disappeared completely 3 years postoperatively (Fig. 1) . She remained free of symptoms following radiosurgery but died of a hypertensive hemorrhage in the left basal ganglion 8 years later.
Case 4. This 19-year-old woman with a midbrain tumor received a VP shunt for hydrocephalus without a mass lesion identified on CT scan. During a shunt revision 5 years later, MR imaging revealed a mass at the rostral part of the quadrigeminal plate and posterior wall of the third ventricle (Fig. 2) . Gamma Knife surgery was performed with a peripheral dose of 13 Gy (maximum dose 43.3 Gy). After treatment, she presented with extrapyramidal symptoms and fluctuating impairment of consciousness (from somnolence to coma) for 6 months. Follow-up MR imaging showed the same tumor size, but diffuse high-signal changes involving bilateral fornices on FLAIR images. It was unclear whether this finding represented radiation-induced changes or artifacts occasionally seen on FLAIR images. Nonetheless, these changes did not explain her serious clinical condition. She was treated with steroids, and eventually made a complete recovery. At the last follow up in 2004 she was asymptomatic, and the tumor as well as the previ- ous signal changes had disappeared completely on MR images.
Case 6. This 9-year-old girl had an 18-month history of headache, nausea, and vomiting. A CT scan revealed a partially enhancing lesion at the tectal area causing hydrocephalus (Fig. 3) . A stereotactic biopsy procedure enabled the diagnosis of a nonpilocytic, low-grade glioma in the patient. She underwent insertion of a VP shunt in 1989. Progression of the tumor prompted treatment with GKS with a peripheral dose of 15.4 Gy. The tumor shrank progressively and disappeared 7 years after treatment. The patient has remained free from symptoms after 15 years of follow up, and is now a college student achieving excellent academic performance.
Case 8. This 7-year-old boy had a 1-month history of right-sided weakness, and was diagnosed with a midbrain tumor in January 1992 (Fig. 4) . Tumor resections were performed in February and March of 1992; the tumors were found to be pilocytic astrocytomas, and the patient showed some clinical improvement after resection. Gamma Knife surgery was performed in October 1993 because of progression of the tumor and recurrent neurological deficits. A dose of 12 Gy was delivered to the periphery of the tumor, and follow-up imaging 6 months later showed a decrease in tumor size. Ten months after GKS treatment, the patient's right-sided hemiparesis and diplopia worsened and he experienced impaired consciousness. Magnetic resonance imaging revealed an enlarging tumor with cystic necrosis and surrounding edema, which prompted a surgical decompression. He recovered uneventfully from the surgery and is now a basketball player with only mild muscle atrophy in his right hand. There was no evidence of tumor recurrence in this patient on the latest MR images 11 years after treatment.
Imaging Outcome
The mean follow-up duration in all patients was 78.0 months (range 5-180 months). Follow-up duration was 15 years in one patient, 12 years in one, 11 years in two, 9 years in one, 8 years in one, 6 years in three, 5 years in four, 4 years in three, 3 years in two, and less than 2 years in two patients. As assessed using MR imaging, the tumors disappeared in four patients, shrank more than 75% in another six, and decreased in the range of 25 to 75% in six patients. The mean duration until the onset of tumor shrinkage was 14.8 months (range 3-46 months).
Four patients had tumor progression. Two patients who initially responded to GKS had tumor regrowth at 10 and 41 months of follow up, respectively. A tumor progressively enlarged in a patient in whom fractionated radiation therapy was planned but failed following GKS with a low peripheral dose of 5 Gy. The fourth patient died of tumor progression.
The univariate analysis identified the following variables as correlated with better tumor response: higher KPS score, higher peripheral dose, smaller tumor volume, and longer symptom duration before GKS. On multivariate analysis, only KPS score correlated with tumor response (Table 2) .
In addition to a change in tumor size, enhancement of the tumor increased in 10 patients between 3 and 18 months of follow up. The onset of increased enhancement occurred after a mean follow up of 6.4 months and ended after a mean follow up of 29.3 months (range 10-48 months). The increase in tumor enhancement did not predict tumor control. An area of low intensity surrounding the tumor on T 1 -weighted MR imaging occurred in eight patients at a mean duration of 5.3 months after GKS and ended after a mean duration of 14.3 months. These imaging changes were independent of target volume or radiosurgical dose. None of the patients developed new clinical symptoms correlated with these imaging changes except for one patient with transient headache.
Clinical Outcome
Of the nine patients whose only symptoms were associated with hydrocephalus and who were successfully treated with a VP shunt before GKS, one patient died of tumor progression and eight were asymptomatic at the last follow up. mild memory loss and ataxia due to hydrocephalus, and the tumor progressed in spite of GKS. A VP shunt relieved the symptoms in this patient.
Of the nine patients with neurological deficits due to local tumor mass effects, in seven the tumor shrank and the neurological deficits improved after GKS. Two patients who initially had improvement of deficits had deterioration in their conditions due to tumor progression. One patient with only mild headache and another with asymptomatic neurofibromatosis at the time of GKS were free of symptoms after a decrease in the size of the tumor. The graph in Fig. 5 shows the tumor progression-free survival rate of all 20 patients (84%) after 5 years.
Discussion
Brainstem gliomas, accounting for only 2% of adult brain tumors, constitute 10 to 20% of central nervous system tumors in the pediatric age group. 13, 17 Due to their critical location, brainstem gliomas have been considered the most difficult brain tumors to treat. Before MR imaging, conventional radiotherapy or chemotherapy were used without considering the histological or biological characteristics of the tumor, and usually yielded disappointing results. After the availability of MR imaging and the accumulation of knowledge regarding the correlation between clinical presentations, tumor locations, growth patterns, and patient outcomes, brainstem gliomas were divided into several subgroups with distinct biological behaviors 17, 21 instead of being categorized as a homogenous pathologic entity. A variety of classification schemes have been proposed, which can essentially be succinctly divided into diffuse or focal tumors.
11,21
Diffuse Brainstem Gliomas
Diffuse intrinsic tumors constitute the majority (75-85%) of brainstem gliomas. 17 These tumors typically exhibit an aggressive biological course and indicate the most serious prognosis. Neither surgery nor radiotherapy has a role in the management of these tumors, 1,5,10,29 and radiosurgery is not an appropriate alternative either.
Focal Brainstem Gliomas
Focal brainstem gliomas are divided into tectal, cervicomedullary junction, and dorsally exophytic tumors; infrequent locations of focal gliomas include the tegmentum, pons, and medulla oblongata. 17, 21 These tumors are typically indolent, developing potentially dangerous long tract and cranial nerve symptoms. Occasionally, obstruction of the aqueduct causes the initial symptoms of hydrocephalus and increased intracranial pressure, prompting imaging studies that lead to the diagnosis. There are four treatment alternatives for managing focal brainstem gliomas. These four options are: 1) shunting and open-ended follow up with neuroimaging; 2) fractionated external beam radiation or brachytherapy; 3) tumor resection; and 4) GKS.
Shunting and Open-Ended Follow Up With Neuroimaging.
Cerebrospinal fluid diversion (shunting) if necessary and periodic MR imaging monitoring have been reported as satisfactory management options of focal brainstem gliomas in most cases. 31, 34, 37, 40, 43, 53 Investigators have reported an uneventful clinical course in patients with focal gliomas managed using this treatment approach, with a mean follow up between 2.6 and 7 years. 6, 8, 31, 43, 51, 53 A small tumor size and a lack of contrast enhancement on MR imaging had been proposed as predictors of a benign clinical course, 8, 41 however, these predictors could not be confirmed either by us or other patient series.
4,40
Fractionated External Beam Radiation or Brachytherapy.
Authors have reported successful results with fractionated radiotherapy in small patient series, 9,40 but generally, conventional radiotherapy with or without combined chemotherapy has limited efficacy. Moreover, in pediatric patients, the side effects of these treatments are significant. 2, 13, 35, 39 Brachytherapy, as reported by Mundinger and colleagues, 32 yielded 5-year patient survival rates with iodine-129 or iodine-125 of 27% and 55%, respectively.
Tumor Resection. With the advancement of microsurgical techniques and neurophysiological monitoring, brainstem tumors are no longer considered surgically inaccessible and several authors have reported impressive results using these techniques. 7, 27, 48, 49 However, it is difficult to interpret these data because some patient series are small and most studies
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Gamma Knife surgery for brainstem gliomas include heterogeneous tumor pathology and location. Lesniak et al. 27 reported survival rates longer than 10 years in all 30 patients with pilocytic astrocytomas and a 22-month median survival rate in 10 patients with fibrillary astrocytomas. In this patient series, 16 patients with pilocytic astrocytomas had tumor recurrence requiring additional surgery or adjuvant radiotherapy, and the overall morbidity rate was 17.5% with moderate disability, 3.5% with severe disability and 1.7% in a vegetative state.
Gamma Knife Surgery. Gamma Knife surgery, originally designed to manage deep intracranial lesions, has emerged as a treatment alternative for focal brainstem gliomas. 15, 20, 24 Fuchs and colleagues 15 treated 12 patients with low-grade brainstem gliomas using GKS and attained tumor control in 11 patients (absent or smaller in six patients, no change in five, and tumor increase in one patient). Kihlstrom and colleagues 24 also reported satisfactory results of GKS in six of seven patients with tumor regression. In the present study, a decrease in size or complete disappearance of the tumor occurred in 16 of 20 patients. The mean duration of follow up in our patient series was 6.5 years, but the natural progression of some of these tumors could be even longer. Therefore, open-ended neuroimaging monitoring will be needed to assess whether the present results will remain consistent in the course of long-term follow up. The outcomes of different approaches for focal brainstem gliomas are summarized in Tables 3 and 4 .
Dose Selection for Gamma Knife Surgery
In the early data of Kihlstrom et al., 24 tumor control was achieved in six of seven patients treated with GKS doses ranging from 14 to 35 Gy, yet the incidence of radiationinduced changes or necrosis accompanied by neurological deficits was high. Six patients developed radiation-induced reactions; one had permanent sequelae and five had tran- (10) total (2); subtotal resection (8) sient neurological deterioration. These investigators subsequently recommended that the dose of GKS should be no greater than 14 Gy for low-grade gliomas. In the patient series reported by Fuchs and colleagues, 15 a peripheral dose of GKS ranging from 9 to 20 Gy (mean 12 Gy) produced good outcomes without complications. The peripheral dose of GKS we used ranged from 10 to 18 Gy, which appeared to be a safe dose that yielded reasonable results. The dose-response effect was not clear from our limited number of patients; however, a higher peripheral dose seemed to be more effective.
Intratumoral Changes in Enhancement
Increased enhancement of the tumor on MR imaging after GKS is presumably due to the breakdown of the bloodbrain barrier and possibly indicates a positive outcome. 22, 24, 38 This imaging enhancement appeared in all patients treated by Kihlstrom et al., 24 who used peripheral doses between 14 and 35 Gy, and in 10 of 16 patients in our series who had a partially enhancing or nonenhancing tumor before GKS. In the present study, however, there was no statistically significant correlation between the enhancement change in the tumor and treatment response.
Problems Using Gamma Knife Surgery in Focal Brainstem Tumors
Before the introduction of MR imaging, biopsy procedures were routinely performed prior to initiating further treatment for brainstem tumors. 48 Since the widespread use of MR imaging, the characteristics of the tumor as seen on MR images and the clinical course usually provide adequate information to enable the physician to diagnose a low-grade tumor. Daglioglu and colleagues 8 reviewed the published series of 118 patients with tectal gliomas in the literature, who had histological data from either biopsy procedures or tumor resection. In these patients, there were 94 low-grade gliomas, 14 high-grade gliomas, and one case each of ependymoma, pineocytoma, and oligodendrogliomas. Seven of the biopsy specimens were inconclusive. In our series, 10 patients did not have histopathological data. The risk of using GKS without histopathological data would be treating patients who might have more benign lesions in the brainstem, such as gangliogliomas, dermoid/ epidermoid cysts, or hemangioblastomas. However, these more benign lesions typically have different MR imaging characteristics (such as cyst formation and heterogeneous enhancement) and can be distinguished from low-grade gliomas. In addition, our policy is to restrict GKS to only those patients with progressing tumors or worsening neurological deficits.
Surgical Complications
A variety of postradiation reactions in the brain, which depend on the time course of GKS, are well described in the conventional radiotherapy literature. Similar reactions have also been observed in radiosurgical patient series. 23, 38 Early reactions usually occur weeks to months after radiotherapy, are generally transient, and require no specific therapy. Although good evidence is lacking, temporary demyelination has been proposed as the underlying mechanism of these reactions. These reactions may be associated with exacerbation of preexisting deficits or the development of new symptoms. Marked somnolence and lethargy have been reported in children treated with whole-brain radiotherapy with a total dose as low as 24 Gy.
14,37 The 7-year-old boy (Case 4) in our series experienced extrapyramidal symptoms and impaired consciousness 1 week after GKS. In this patient FLAIR imaging revealed high signal changes involving the fornices bilaterally. However, these changes could have been MR imaging artifacts and did not explain the clinical syndrome.
A low-intensity area surrounding the treated lesion that develops after radiosurgery has been reported in the literature, but the mechanism of this area is not yet clear. Occasionally, this change leads to transient neurological deterioration. In our patient series, a small low-intensity area surrounding the tumor on T 1 -weighted MR imaging was observed in eight patients. One of these patients presented with transient headache.
The nature of late radiation-induced changes in the brain as seen on MR imaging months to years after treatment remains to be elucidated. These changes presumably represent an array of pathological processes, ranging from gliosis to true necrosis. It is important to emphasize that the signal changes on MR images associated with clinical deterioration are too frequently interpreted as radionecrosis despite the fact that the changes are usually transitory. 36 The tumor in one patient in our study (Case 8) became necrotic following GKS. The patient's clinical condition deteriorated and he again required surgery. The necrotic tumor was able to be extirpated quickly and completely without trauma, which was not possible during two previous resection attempts. However, this observation still does not allow us (1) progression (4) worse (3) to contend that radiosurgically induced necrosis of a tumor before surgery could be beneficial. A few isolated cases of secondary tumor development after GKS have been reported. 28 At the University of Virginia, we reviewed the cases of 1333 patients with AVMs treated using the Gamma Knife; 288 of the patients underwent follow-up imaging for at least 10 years. We observed meningioma formation in two patients with AVMs longer than 10 years after GKS; this translates to an incidence of radiosurgically induced neoplasia of 69 in 100,000 person-years. 44 Considering the long latency of tumor induction, however, this incidence rate is not inconsequential if one considers only those patients with long-term follow up. Continuous observation is prudent in these patients, particularly in the vulnerable young patients who are expected to have a long survival.
Conclusions
For intracranial glial tumors, survival following microsurgery has been correlated with the extent of resection. 39, 42, 52 When tumors involve critical areas, safe maximum cytoreduction with acceptable morbidity should be the goal of treatment. Using GKS appears to be safe and effective for focal brainstem gliomas. Therefore, its use as an initial treatment or adjunct in partially extirpated tumors appears to be important.
